Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-1.75M | $-0.01 |
| 2024 | $0.00 | $-1.14M | $-0.01 |
| 2023 | $0.00 | $-2.13M | $-0.02 |
| 2022 | $276.3K | $-348.9K | $-0.01 |
| 2021 | $921.3K | $-126.5K | $-0.00 |
Social Signal Score
Valuation
AVAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Negative
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the deve
View source ↗